|
Key Drug Pipeline Databases on Dialog
Lesson 3:
Pharmaprojects
(File 128/928)
• Objectives
• About Pharmaprojects
• Why Pharmaprojects?
• The Record
• Exercises
• Summary
• Glossary
• Print Tips
• About the Icons
Links to Other Lessons:
Technical Help
with Online Courses
Need Help?
E-mail the
|
|
|
|
Lesson 3: Pharmaprojects (File 128/928)
Why Use Pharmaprojects?
Each file on Dialog has its advantages. Note the major benefits of this file below.
- Monitors global drug development including 40 countries representing major world markets.
- Summarizes information about forthcoming products and provides additional drug nomenclature for follow-up in medical bibliographic files.
- Both IMS and Pharmaprojects use an adaptation of a therapeutic classification scheme developed by the European Pharmaceutical Market Research Association (EPhMRA).
- Includes drug information: molecular formula,
laboratory codes, therapeutic class codes, CAS
Registry Number, protein target data, Lipinsky “Rule
of 5” data, pharmacology and pharmacokinetic
details.
- Includes searchable target family and target
data so that you can identify all drugs acting
on a specific protein target.
- Includes update information which enables you
to identify all drugs that have been discontinued
due to efficacy or adverse events.
- Useful for monitoring pre-registration submissions to government agencies and registrations (approvals) of new drugs worldwide.
- Contains the best coverage of biotechnological products, new formulation and combinations under development anywhere in the world.
- Reports on progress of new chemical and biological
products with therapeutic potential throughout
their R&D cycles, from early pharmacological
studies to final launch on major markets worldwide.
- Contains new records for products just entering the R&D pipeline and revisions to extant references, recording milestones such as nomenclature changes, transition from animal to human studies, submission of documents to gain regulatory approval, final registration in given countries, product launch, or discontinuation.
Go to the next page.
3-3
|
|